This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Senesco Provides SNS01-T Update On Phase 1b/2a Multiple Myeloma Trial

Stocks in this article: SNT

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

To date five patients have been enrolled into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.

“We are encouraged that there is an indication that SNS01-T is performing as designed even at this low dose,” stated Harlan Waksal, M.D., Chairman of Senesco. “At this dose level we had expected to evaluate only safety. So seeing an indication of activity, even in a single patient, is a bonus.”

In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.

“We are pleased that the SNS01-T study is progressing well. Provided there are no more withdrawals we expect to complete the first dosing group during the last week of June,” stated Leslie J. Browne, Ph.D., President and Chief Executive Officer of Senesco. “Although we experienced an initial delay in patient enrollment, we believe that the rate of recruitment into the study is back on plan.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,587.41 -91.29 -0.52%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs